Saniona AB: Saniona and Boehringer Ingelheim sign

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Saniona AB: Saniona and Boehringer Ingelheim sign collaboration agreement in schizophrenia

PRESS RELEASE

August 29, 2016

  • The collaboration aims to develop innovative new treatment options for patients with schizophrenia  
  • In the EU, at least 164 million people (38%) suffer from mental health problems. [i] , Overall, the burden of mental illness continues to grow. [ii]

Boehringer Ingelheim, one of the world's 20 leading pharmaceutical companies, and Saniona, a leading biotech company in the field of ion channel drug discovery, today announced that they have entered into a research collaboration with the objective to discover and develop novel compounds for the treatment of schizophrenia. Saniona may receive up to €90 million in milestone payments including an upfront payment of €5 million upon signing of the agreement. Furthermore, Saniona is eligible to receive royalties on worldwide net sales of any resulting products under the collaboration. 

The joint research activities aim to identify compounds that could be capable of restoring brain network activity in patients with schizophrenia. The neuronal activity in the brain of such patients can be impaired by a functional imbalance between stimulating (excitatory) and inhibitory transmission of signals between neurons.

The program aligns with Boehringer Ingelheim's drug discovery strategy for neuropsychiatric diseases which focuses on systematically investigating dominant symptom domains and the underlying neurobiology across mental disorders such as schizophrenia, Alzheimer's disease and depression.

 "We are very pleased to be working with Saniona's experienced scientific and management team and to build on their ion channel drug discovery platform. Working together and blending our joint expertise and capabilities, we have the potential to advance new treatment options for schizophrenia" says Clive R. Wood, Ph.D., Senior Corporate Vice President, Discovery Research at Boehringer Ingelheim.

Saniona will receive an upfront payment of €5 million upon signing of the agreement and milestone payments of up to €50 million upon the achievement of certain research, development and regulatory milestones. In addition, Saniona is entitled to commercial milestone payments of up to €35 million and tiered royalties on net sales of any potential products commercialised by Boehringer Ingelheim as a result of this collaboration. Further financial details were not disclosed.

"We are delighted to have Boehringer Ingelheim as partner for our schizophrenia program. My team and I have worked in a long lasting partnership with Boehringer Ingelheim before and I can truly say that this is one of our preferred partners. We have a high respect for their diligent and result oriented R&D operations, their company values, and their effective and respectful collaborations with partners" says Jørgen Drejer, CEO of Saniona.

Saniona grants Boehringer Ingelheim exclusive worldwide rights to research, develop, manufacture and commercialise medicines identified through the collaboration. In addition to upfront and milestone payments and royalties on net sales, Saniona will receive undisclosed research funding during the joint research period.

According to the World Health Organisation, mental illness, together with substance abuse disorders remains the leading cause of disability worldwide. In the EU, at least 164 million people (38%) suffer from mental health problems. People with schizophrenia often have problems in many areas of cognition, [iii] severely impacting their ability to live or function 'normally'. As a consequence, large numbers of people with schizophrenia are isolated, unemployed and/or homeless. [iv]

For more information, please contact

Thomas Feldthus, EVP and CFO, Saniona, Mobile: +45 2210 9957, E-mail: tf@saniona.com

Julia Meyer-Kleinmann, Director Corporate Communications, Boehringer Ingelheim, Email:  m-kleinmann@boehringer-ingelheim.com , Mobile: +49 178 290 8178

This information is information that Saniona (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person of Saniona set out above, at 08:30 CET on August 29, 2016.

About Boehringer Ingelheim

Boehringer Ingelheim is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, Boehringer Ingelheim operates globally through 145 affiliates and a total of some 47,500 employees. The focus of the family-owned company, founded in 1885, is on researching, developing, manufacturing and marketing new medications of high therapeutic value for human and veterinary medicine. Social responsibility is an important element of the corporate culture at Boehringer Ingelheim. This includes worldwide involvement in social projects through, for example, the initiative "Making More Health" while also caring for employees. Respect, equal opportunity and reconciling career and family form the foundation of mutual cooperation. The company also focuses on environmental protection and sustainability in everything it does. In 2015, Boehringer Ingelheim achieved net sales of about 14.8 billion euros. R&D expenditure corresponds to 20.3 per cent of net sales. www.boehringer-ingelheim.com

About Saniona

Saniona is a research and development company focused on drugs for diseases of the central nervous system, autoimmune diseases, metabolic diseases and treatment of pain. The company has a significant portfolio of potential drug candidates at pre-clinical and clinical stage. The research is focused on ion channels, which makes up a unique protein class that enables and controls the passage of charged ions across cell membranes. Saniona has ongoing collaboration agreements with Upsher-Smith Laboratories, Inc., Productos Medix, S.A de S.V and Saniona's Boston based spinout Ataxion Inc., which is financed by Atlas Venture Inc. and Biogen Inc. Saniona is based in Copenhagen, Denmark, where it has a research center of high international standard. Saniona is listed at Nasdaq First North Premier and has about 4,400 shareholders. Pareto Securities is Certified Advisor for Saniona. The company's share is traded under the ticker SANION. Read more at www.saniona.com .

[i] Wittchen HU, et al . The size and burden of mental disorders and other disorders of the brain in Europe 2010. Eur Neuropsychopharmacol . 2011;21:655-79.

[ii] World Health Organization. Mental disorders. Fact sheet no. 396, updated October 2015. Available at: http://www.who.int/mediacentre/factsheets/fs396/en/ Last accessed March 2016.

[iii] Sheffield JM, et al . Common and specific cognitive deficits in schizophrenia: relationships to function. Cogn Affect Behav Neurosci. 2014;14:161-74.

[iv] Kooyman I, et al. Outcomes of public concern in schizophrenia. Br J Psychiatry . 2007;191(Suppl.50):s29-s36.

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Elisity’s Texas Water Pilot Puts IonQ’s Deal in View

Updated Category News Views 45

Water-system security is not a place for chest-thumping Elisity’s role in Texas Project Watershed 250 lands on a problem that is painfully concrete: water and wastewater utilities have to keep pumps, treatment systems and plant operations running while trying to close cybersecurity gaps. That is a tougher job than selling another dashboard to a corporate IT department....

Continue Reading
Ross Pools Joins Forces with Florida Panthers in 2026

Updated Category News Views 327

An Unlikely Team-Up: Pools and Hockey Well, here's one for the books: a South Florida pool company hitching its wagon to an NHL team. Ross Pools, the folks who’ve been carving out backyard oases in the sizzling Florida sun for over two decades, are now officially aligned with the Florida Panthers. Yeah, the same Panthers that snatched the Stanley Cup not once but twice...

Continue Reading
Arbor Realty Trust Faces Securities Fraud Allegations

Updated Category News Views 108

Securities Lawsuit Against Arbor Realty Trust Looms Well, here we go again. Another day, another securities lawsuit hitting the headlines. This time it's Arbor Realty Trust (NYSE: ABR) getting caught in the crossfire, accused of pulling the wool over investors' eyes. Seems like 'truth in advertising' is just part of the PR playbook for some big shots. Understanding the...

Continue Reading
Sabre Unveils AI Travel Tech: A Bold New Frontier

Updated Category News Views 110

Sabre's Game-Changing AI Travel Integration I'm no stranger to bold moves in the travel industry, but what Sabre's rolling out tomorrow might just be the biggest leap we've seen in a while. They're unleashing what's called the first global travel plug-in within Grok Bot, marking a significant shake-up in the travel tech sphere. Too many tech upgrades in this business...

Continue Reading
Snowhawk Enters Telarus as Digital Demand Gets Serious

Updated Category News Views 17

Telarus just pulled another serious capital partner into the room, and that matters more than the usual law-firm victory lap. Snowhawk Partners has invested in the technology services distributor alongside Columbia Capital, which remains a long-standing partner. Nobody disclosed a valuation, ownership percentage, financing mix, or closing date. Annoying? Sure. But the...

Continue Reading
Graphic Packaging Shakes Up Leadership and Supply Chain

Updated Category News Views 226

New Leadership Takes the Helm at Graphic Packaging What do you do when you want to streamline an operation that spans continents? Well, if you're Graphic Packaging Holding Company (NYSE: GPK), you bring in fresh leadership to serenade the chaos into a well-oiled machine. Starting December 1, 2026, D. Keith Hamilton will be sinking his teeth into North America Mills &...

Continue Reading
Palm Beach Loan Company Tests Luxury Lending Demand

Updated Category News Views 0

Jewelry in a safe is dead capital until somebody lends against it. That plain fact sits behind Luxury Asset Capital's latest move: the launch of Palm Beach Loan Company, a South Florida brand aimed at wealthy owners of watches, diamonds, art, handbags, gold, collectibles, and other high-value possessions. The company is not asking clients to sell the stuff they spent...

Continue Reading
Tenax Class Action: Investors Alley Fight for Redress

Updated Category News Views 179

Tenax Therapeutics in Hot Water Over Drug Trial Results Amidst the ever-unpredictable tides of the pharmaceutical industry, here comes a doozy – Tenax Therapeutics, Inc. is neck-deep in a shareholder lawsuit. If you tossed some money at NASDAQ:TENX anytime between November 13, 2023, and August 7, 2026, you might be feeling the sting of regret, and rightly so. What Went...

Continue Reading
Greenberg Traurig Cheers Clients' 69th GRAMMY® Nods

Updated Category News Views 124

A Momentous Occasion for Greenberg Traurig's Entertainment Clients Oh, the glamour and glitz of the music world! There's nothing quite like the GRAMMY® Awards to stir up a blend of excitement, ego, and anxiety in the industry. This time around, the lawyers over at Greenberg Traurig are beaming with pride as their clients scoop up nominations for the 69th Annual GRAMMY®...

Continue Reading
Portillo's Faces Legal Heat: Investor Class Action Filed

Updated Category News Views 268

What’s Eating Portillo's? Ah, once upon a misstep in the land of promising expansion, now we have Portillo's Inc. (NASDAQ: PTLO) neck-deep in legal hot water. Those golden fries and famous sandwiches somehow didn't pave the way for stockholder bliss. Why the turmoil? On an ordinary November morning, the DJS Law Group made it clear: They're rallying the troops for a...

Continue Reading

Top 5 Most Recently Viewed Articles

Exciting New Dining and Shopping Experiences Coming to Cotino

Updated Category News Views 309

Exciting Developments at Cotino Bay Beach A vibrant new community is set to emerge with the opening of Cotino Bay Beach, Dining and Shops in fall 2026. The first Storyliving by Disney community is gearing up to offer an array of dining and retail experiences, creating a unique destination for residents and visitors alike. Restaurants to Enrich the Community Among the...

Continue Reading
dsm-firmenich Expands Share Repurchase Program for Growth

Updated Category News Views 227

Introduction to the Share Repurchase Program dsm-firmenich, a leader in nutrition, health, and beauty, has embarked on a significant share repurchase program with the aim of enhancing shareholder value and strategically managing its capital. By initiating this buyback, dsm-firmenich demonstrates its commitment to returning value to its investors while still investing in...

Continue Reading
Investigation into Arvinas, Inc. Over Securities Fraud Claims

Updated Category News Views 561

Investigation of Arvinas, Inc. Pomerantz LLP is looking into potential claims on behalf of investors of Arvinas, Inc. (NASDAQ: ARVN). This investigation aims to uncover whether the company and its executives may have engaged in securities fraud or other illegal business practices. Recent Developments Arvinas has recently communicated significant changes to its clinical...

Continue Reading
Gantry Enhances Mortgage Banking with Triad Capital Acquisition

Updated Category News Views 145

Gantry got its hands on Triad Capital Advisors back in 2023, and it was no small move. This merger wasn't just about beefing up their operational muscle; it expanded Gantry's footprint in the Midwest finance scene big time. It’s like they dropped a bomb on their competitors without warning—traders watching closely could feel the shift coming. With this acquisition,...

Continue Reading
Port Athena Debuts with PENETRON Solution in Tartu

Updated Category News Views 32

The Emergence of Port Athena in Tartu Move over, sleepy towns—Tartu's staking its claim with the Port Athena development. What we're looking at is more than just another block of buildings. It's practically a new district, nestled on the banks of the Emajõgi River. Forget the stereotypical old-world charm; we're talking sleek, modern architecture that's ready to become...

Continue Reading